Cell mediated immune response after challenge in Omp25 liposome immunized mice contributes to protection against virulent Brucella abortus 544

Vaccine

Volumn 31, Issue 8, 2013, Pages 1231-1237

  Goel, Divya ^a   Rajendran, Vinoth ^b   Ghosh, Prahlad C ^b   Bhatnagar, Rakesh ^a  

^a JAWAHARLAL NEHRU UNIVERSITY   (India)

^b UNIVERSITY OF DELHI   (India)

Author keywords

Brucella; Cytotoxicity; Liposome; Microparticle; Omp25; Th2 response

Indexed keywords

BRUCELLA VACCINE; LIPOSOME; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; POLYGLACTIN; RECOMBINANT OMP25; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL VIRULENCE; BRUCELLA ABORTUS; BRUCELLOSIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG FORMULATION; FEMALE; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; SINGLE DRUG DOSE;

ANIMALS; BACTERIAL OUTER MEMBRANE PROTEINS; BRUCELLA ABORTUS; BRUCELLA VACCINE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; DRUG CARRIERS; FEMALE; LACTIC ACID; LIPOSOMES; MICE; MICE, INBRED BALB C; POLYGLYCOLIC ACID; VACCINES, SUBUNIT; VACCINES, SYNTHETIC;

EID: 84873082795     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.12.043     Document Type: Article

References (35)

1. Pappas G., Papadimitriou P., Christou L., Akritidis N. Future trends in human brucellosis treatment. Expert Opin Investig Drugs 2006, 15:1141-1149.
2. Godfroid J., Cloeckaert A., Liautard J.P., Kohler S., Fretin D., Walravens K., et al. From the discovery of the Malta fever's agent to the discovery of a marine mammal reservoir, brucellosis has continuously been a re-emerging zoonosis. Vet Res 2005, 36:313-326.
3. Nicoletti P. Vaccination against Brucella. Adv Biotechnol Processes 1990, 13:147-168.
4. Baldwin C.L., Goenka R. Host immune responses to the intracellular bacteria Brucella: does the bacteria instruct the host to facilitate chronic infection. Crit Rev Immunol 2006, 26:407-442.
5. Bowden R.A., Cloeckaert A., Zygmunt M.S., Dubray G. Outer-membrane protein- and rough lipopolysaccharide-specific monoclonal antibodies protect mice against Brucella ovis. J Med Microbiol 1995, 43:344-347.
6. Bowden R.A., Cloeckaert A., Zygmunt M.S., Dubray G. Evaluation of immunogenicity and protective activity in BALB/c mice of the 25-kDa major outer-membrane protein of Brucella melitensis (Omp25) expressed in Escherichia coli. J Med Microbiol 1998, 47:39-48.
7. Dubray G., Bezard G. Isolation of three Brucella abortus cell-wall antigens protective in murine experimental brucellosis. Ann Rech Vet 1980, 11:367-373.
8. Cloeckaert A., Verger J.M., Grayon M., Vizcaino N. Molecular and immunological characterization of the major outer membrane proteins of Brucella. FEMS Microbiol Lett 1996, 145:1-8.
9. Bowden R.A., Cloeckaert A., Zygmunt M.S., Bernard S., Dubray G. Surface exposure of outer membrane protein and lipopolysaccharide epitopes in Brucella species studied by enzyme-linked immunosorbent assay and flow cytometry. Infect Immun 1995, 63:3945-3952.
10. Cloeckaert A., Verger J.M., Grayon M., Grepinet O Restriction site polymorphism of the genes encoding the major 25kDa and 36kDa outer-membrane proteins of Brucella. Microbiology 1995, 141(Pt. 9):2111-2121.
11. Jubier-Maurin V., Boigegrain R.A., Cloeckaert A., Gross A., Alvarez-Martinez M.T., Terraza A., et al. Major outer membrane protein Omp25 of Brucella suis is involved in inhibition of tumor necrosis factor alpha production during infection of human macrophages. Infect Immun 2001, 69:4823-4830.
12. Edmonds M.D., Cloeckaert A., Elzer P.H. Brucella species lacking the major outer membrane protein Omp25 are attenuated in mice and protect against Brucella melitensis and Brucella ovis. Vet Microbiol 2002, 88:205-221.
13. Edmonds M.D., Cloeckaert A., Booth N.J., Fulton W.T., Hagius S.D., Walker J.V., et al. Attenuation of a Brucella abortus mutant lacking a major 25kDa outer membrane protein in cattle. Am J Vet Res 2001, 62:1461-1466.
14. Commander N.J., Spencer S.A., Wren B.W., MacMillan A.P. The identification of two protective DNA vaccines from a panel of five plasmid constructs encoding Brucella melitensis 16M genes. Vaccine 2007, 25:43-54.
15. Zhan Y., Kelso A., Cheers C. Cytokine production in the murine response to brucella infection or immunization with antigenic extracts. Immunology 1993, 80:458-464.
16. Maulding H.V. Prolonged delivery of peptides by microcapsules. J Control Release 1987, 6:167-176.
17. Garcon N.M., Six H.R. Universal vaccine carrier. Liposomes that provide T-dependent help to weak antigens. J Immunol 1991, 146:3697-3702.
18. Alving C.R. Liposomes as carriers of antigens and adjuvants. J Immunol Methods 1991, 140:1-13.
19. Davis D., Gregoriadis G. Liposomes as adjuvants with immunopurified tetanus toxoid: influence of liposomal characteristics. Immunology 1987, 61:229-234.
20. Antimisiaris S.G., Jayasekera P., Gregoriadis G. Liposomes as vaccine carriers. Incorporation of soluble and particulate antigens in giant vesicles. J Immunol Methods 1993, 166:271-280.
21. Allison A.C. Adjuvants and immune enhancement. Int J Technol Assess Health Care 1994, 10:107-120.
22. Cohen S., Alonso M.J., Langer R. Novel approaches to controlled-release antigen delivery. Int J Technol Assess Health Care 1994, 10:121-130.
23. Gregoriadis G. Liposomes as immunoadjuvants and vaccine carriers: antigen entrapment. Immunomethods 1994, 4:210-216.
24. Gregoriadis G., McCormack B., Obrenovic M., Saffie R., Zadi B., Perrie Y. Vaccine entrapment in liposomes. Methods 1999, 19:156-162.
25. Muttilainen S., Idanpaan-Heikkila I., Wahlstrom E., Nurminen M., Makela P.H., Sarvas M. The Neisseria meningitidis outer membrane protein P1 produced in Bacillus subtilis and reconstituted into phospholipid vesicles elicits antibodies to native P1 epitopes. Microb Pathog 1995, 18:423-436.
26. Amorena B., Baselga R., Albizu I. Use of liposome-immunopotentiated exopolysaccharide as a component of an ovine mastitis staphylococcal vaccine. Vaccine 1994, 12:243-249.
27. Abraham E., Shah S. Intranasal immunization with liposomes containing IL-2 enhances bacterial polysaccharide antigen-specific pulmonary secretory antibody response. J Immunol 1992, 149:3719-3726.
28. Goel D., Bhatnagar R. Intradermal immunization with outer membrane protein 25 protects Balb/c mice from virulent B. abortus 544. Mol Immunol 2012, 51:159-168.
29. Bukata L., Altabe S., de Mendoza D., Ugalde R.A., Comerci D.J. Phosphatidylethanolamine synthesis is required for optimal virulence of Brucella abortus. J Bacteriol 2008, 190:8197-8203.
30. Jiang X., Baldwin C.L. Effects of cytokines on intracellular growth of Brucella abortus. Infect Immun 1993, 61:124-134.
31. Murphy E.A., Sathiyaseelan J., Parent M.A., Zou B., Baldwin C.L. Interferon-gamma is crucial for surviving a Brucella abortus infection in both resistant C57BL/6 and susceptible BALB/c mice. Immunology 2001, 103:511-518.
32. Svetic A., Jian Y.C., Lu P., Finkelman F.D., Gause W.C. Brucella abortus induces a novel cytokine gene expression pattern characterized by elevated IL-10 and IFN-gamma in CD4+ T cells. Int Immunol 1993, 5:877-883.
33. Barquero-Calvo E., Chaves-Olarte E., Weiss D.S., Guzman-Verri C., Chacon-Diaz C., Rucavado A., et al. Brucella abortus uses a stealthy strategy to avoid activation of the innate immune system during the onset of infection. PLoS ONE 2007, 2:e631.
34. Zhan Y., Cheers C. Control of IL-12 and IFN-gamma production in response to live or dead bacteria by TNF and other factors. J Immunol 1998, 161:1447-1453.
35. Zhan Y., Liu Z., Cheers C. Tumor necrosis factor alpha and interleukin-12 contribute to resistance to the intracellular bacterium Brucella abortus by different mechanisms. Infect Immun 1996, 64:2782-2786.